The CBO has said the restrictions would save the federal government about $2.7 billion over 10 years and the FTC said it could save American consumers at least $3.5 billion a year.
The study was authored by Jonathan Orszag, a former member of President Bill ClintonBill ClintonWe must act now and pass the American Health Care Act Trump's message: Russia First or America First? Senate Democrats should grill Judge Gorsuch on antitrust. Here's how. MORE’s National Economic Council; Bret Dickey, Senior Vice President with the economic consulting firm Compass Lexecon; and Robert Willig, Professor of Economics and Public Affairs at Princeton University.
The trade group representing the generic drug industry immediately praised the study.
"This new analysis refutes the flawed assumptions that have been used as the foundation of pending legislation to ban patent settlements," the Generic Pharmaceutical Association said in a statement. "The faulty assumptions include: (1) the conclusion that banning settlements will accelerate generic competition; (2) that banning settlements will save money; and (3) that further restrictions on settlements are needed beyond the authority FTC currently has to police patent settlements and reject those that are anti-competitive."
The House has already passed "pay-for-delay" legislation and it has also been attached to the Senate's pending FY2011 Financial Services Appropriations bill.